These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18536916)

  • 1. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.
    Limouris GS; Chatziioannou A; Kontogeorgakos D; Mourikis D; Lyra M; Dimitriou P; Stavraka A; Gouliamos A; Vlahos L
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1827-37. PubMed ID: 18536916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
    Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
    Kratochwil C; López-Benítez R; Mier W; Haufe S; Isermann B; Kauczor HU; Choyke PL; Haberkorn U; Giesel FL
    Endocr Relat Cancer; 2011 Oct; 18(5):595-602. PubMed ID: 21791571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-specific dosimetry calculations using mathematic models of different anatomic sizes during therapy with 111In-DTPA-D-Phe1-octreotide infusions after catheterization of the hepatic artery.
    Kontogeorgakos DK; Dimitriou PA; Limouris GS; Vlahos LJ
    J Nucl Med; 2006 Sep; 47(9):1476-82. PubMed ID: 16954556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.
    McStay MK; Maudgil D; Williams M; Tibballs JM; Watkinson AF; Caplin ME; Buscombe JR
    Radiology; 2005 Nov; 237(2):718-26. PubMed ID: 16192318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
    Ebbers SC; Braat AJAT; Moelker A; Stokkel MPM; Lam MGEH; Barentsz MW
    Trials; 2020 Feb; 21(1):141. PubMed ID: 32024533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.
    Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; deHerder WW; vanEijck CH; Kwekkeboom DJ; deJong M; Pauwels S
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S219-23. PubMed ID: 10604135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy.
    Giesel FL; Wulfert S; Zechmann CM; Haberkorn U; Kratochwil C; Flechsig P; Kuder T; Schwartz LH; Bruchertseifer F
    Exp Oncol; 2013 Jun; 35(2):122-6. PubMed ID: 23828389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
    Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
    Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.
    Lacin S; Oz I; Ozkan E; Kucuk O; Bilgic S
    Cancer Biother Radiopharm; 2011 Oct; 26(5):631-7. PubMed ID: 21950557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraarterial Peptide Receptor Radionuclide Therapy Using
    Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
    J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.
    Limouris GS; Dimitropoulos N; Kontogeorgakos D; Papanikolos G; Koutoulidis V; Hatzioannou A; Mourikis D; Lyra M; Dimitriou P; Stravaka A; Vlahos L
    Cancer Biother Radiopharm; 2005 Apr; 20(2):215-7. PubMed ID: 15869458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center.
    Arslan N; Emi M; Alagöz E; Ustünsöz B; Oysul K; Arpaci F; Uğurel S; Beyzadeoğlu M; Ozgüven MA
    Vojnosanit Pregl; 2011 Apr; 68(4):341-8. PubMed ID: 21627019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine tumors: a focus on liver metastatic lesions.
    Limouris GS
    Front Oncol; 2012; 2():20. PubMed ID: 22655264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.
    Tiensuu Janson E; Eriksson B; Oberg K; Skogseid B; Ohrvall U; Nilsson S; Westlin JE
    Acta Oncol; 1999; 38(3):373-7. PubMed ID: 10380830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.
    Valkema R; De Jong M; Bakker WH; Breeman WA; Kooij PP; Lugtenburg PJ; De Jong FH; Christiansen A; Kam BL; De Herder WW; Stridsberg M; Lindemans J; Ensing G; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):110-22. PubMed ID: 11965606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.